{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T23:20:00Z","timestamp":1787872800283,"version":"build-2784847793"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02994-w","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T23:03:07Z","timestamp":1787871787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Three-year adjuvant treatment of icotinib in stage II-IIIA EGFR-mutated lung adenocarcinoma (ICWIP): a randomized, double-blind, placebo-controlled phase 3 trial"],"prefix":"10.1038","volume":"11","author":[{"given":"Yu-Tao","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Hong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Yi","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Ruo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hua","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Cai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Feng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-Lan","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3342-4964","authenticated-orcid":false,"given":"Yuan-Kai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"2994_CR1","volume":"76","author":"H Sung","year":"2026","unstructured":"Sung, H. et al. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA Cancer J. Clin. 76, e70090 (2026).","journal-title":"CA Cancer J. Clin."},{"key":"2994_CR2","doi-asserted-by":"publisher","first-page":"112023","DOI":"10.1016\/j.envres.2021.112023","volume":"204","author":"X Yang","year":"2022","unstructured":"Yang, X., Zhang, T., Zhang, X., Chu, C. & Sang, S. Global burden of lung cancer attributable to ambient fine particulate matter pollution in 204 countries and territories, 1990-2019. Environ. Res 204, 112023 (2022).","journal-title":"Environ. Res"},{"key":"2994_CR3","doi-asserted-by":"crossref","unstructured":"Meyer, M. L. et al. New promises and challenges in the treatment of advanced non-small cell lung cancer. Lancet 404, 803\u2013822 (2024).","DOI":"10.1016\/S0140-6736(24)01029-8"},{"key":"2994_CR4","doi-asserted-by":"crossref","unstructured":"Imai, H. et al. Course of postoperative relapse in non-small cell lung cancer is strongly associated with postprogression survival. Thorac. Cancer 12, 2740\u20132748 (2021).","DOI":"10.1111\/1759-7714.14119"},{"key":"2994_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1200\/JCO.2009.23.2272","volume":"28","author":"R Arriagada","year":"2010","unstructured":"Arriagada, R. et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J. Clin. Oncol. 28, 35\u201342 (2010).","journal-title":"J. Clin. Oncol."},{"key":"2994_CR6","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/NEJMoa031644","volume":"350","author":"R Arriagada","year":"2004","unstructured":"Arriagada, R. et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N. Engl. J. Med. 350, 351\u2013360 (2004).","journal-title":"N. Engl. J. Med."},{"key":"2994_CR7","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","volume":"26","author":"JP Pignon","year":"2008","unstructured":"Pignon, J. P. et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J. Clin. Oncol. 26, 3552\u20133559 (2008).","journal-title":"J. Clin. Oncol."},{"key":"2994_CR8","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1016\/S1470-2045(17)30691-5","volume":"18","author":"HA Wakelee","year":"2017","unstructured":"Wakelee, H. A. et al. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small cell lung cancer (E1505): an open-label, multicentre, randomized, phase 3 trial. Lancet Oncol. 18, 1610\u20131623 (2017).","journal-title":"Lancet Oncol."},{"key":"2994_CR9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","volume":"22","author":"F Zhou","year":"2025","unstructured":"Zhou, F. et al. The changing treatment landscape of EGFR-mutant non-small cell lung cancer. Nat. Rev. Clin. Oncol. 22, 95\u2013116 (2025).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2994_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.lungcan.2017.08.021","volume":"113","author":"B Han","year":"2017","unstructured":"Han, B. et al. EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study. Lung Cancer 113, 37\u201344 (2017).","journal-title":"Lung Cancer"},{"key":"2994_CR11","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1200\/JCO.2015.61.8918","volume":"33","author":"K Kelly","year":"2015","unstructured":"Kelly, K. et al. Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small cell lung cancer (RADIANT): a randomized, double-blind, phase III trial. J. Clin. Oncol. 33, 4007\u20134014 (2015).","journal-title":"J. Clin. Oncol."},{"key":"2994_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S1470-2045(17)30729-5","volume":"19","author":"WZ Zhong","year":"2018","unstructured":"Zhong, W. Z. et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT\/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 19, 139\u2013148 (2018).","journal-title":"Lancet Oncol."},{"key":"2994_CR13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1200\/JCO.21.01729","volume":"40","author":"H Tada","year":"2022","unstructured":"Tada, H. et al. Randomized phase III study of gefitinib versus cisplatin plus vinorelbine for patients with resected stage II-IIIA non-small cell lung cancer with EGFR mutation (IMPACT). J. Clin. Oncol. 40, 231\u2013241 (2022).","journal-title":"J. Clin. Oncol."},{"key":"2994_CR14","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S2213-2600(18)30277-7","volume":"6","author":"D Yue","year":"2018","unstructured":"Yue, D. et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small cell lung cancer (EVAN): a randomized, open-label, phase 2 trial. Lancet Respir. Med. 6, 863\u2013873 (2018).","journal-title":"Lancet Respir. Med."},{"key":"2994_CR15","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S2213-2600(21)00134-X","volume":"9","author":"J He","year":"2021","unstructured":"He, J. et al. Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small cell lung cancer (EVIDENCE): a randomized, open-label, phase 3 trial. Lancet Respir. Med. 9, 1021\u20131029 (2021).","journal-title":"Lancet Respir. Med."},{"key":"2994_CR16","doi-asserted-by":"publisher","first-page":"101565","DOI":"10.1016\/j.esmoop.2023.101565","volume":"8","author":"C Lv","year":"2023","unstructured":"Lv, C. et al. Randomized phase II adjuvant trial to compare two treatment durations of icotinib (2 years versus 1 year) for stage II-IIIA EGFR-positive lung adenocarcinoma patients (ICOMPARE study). ESMO Open 8, 101565 (2023).","journal-title":"ESMO Open"},{"key":"2994_CR17","doi-asserted-by":"publisher","first-page":"101839","DOI":"10.1016\/j.eclinm.2023.101839","volume":"57","author":"W Ou","year":"2023","unstructured":"Ou, W. et al. Adjuvant icotinib versus observation in patients with completely resected EGFR-mutated stage IB NSCLC (GASTO1003, CORIN): a randomized, open-label, phase 2 trial. EClinicalMedicine 57, 101839 (2023).","journal-title":"EClinicalMedicine"},{"key":"2994_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s10637-022-01316-5","volume":"41","author":"K Qian","year":"2023","unstructured":"Qian, K. et al. Icotinib, an EGFR tyrosine kinase inhibitor, as adjuvant therapy for patients with stage IIA-IIIA EGFR-mutant non-small cell lung adenocarcinoma: a multicenter, open-label, single-arm, phase II study (ICAPE). Investig. New Drugs 41, 44\u201352 (2023).","journal-title":"Investig. New Drugs"},{"key":"2994_CR19","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41392-025-02358-w","volume":"10","author":"N Li","year":"2025","unstructured":"Li, N. et al. Adjuvant icotinib for resected EGFR-mutated stage II-IIIA non-small cell lung cancer (ICTAN, GASTO1002): a randomized comparison study. Signal Transduct. Target. Ther. 10, 273 (2025).","journal-title":"Signal Transduct. Target. Ther."},{"key":"2994_CR20","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","volume":"383","author":"YL Wu","year":"2020","unstructured":"Wu, Y. L. et al. Osimertinib in resected EGFR-mutated non-small cell lung cancer. N. Engl. J. Med. 383, 1711\u20131723 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2994_CR21","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.2147\/CMAR.S240275","volume":"12","author":"YT Liu","year":"2020","unstructured":"Liu, Y. T. et al. Icotinib as adjuvant treatment for stage II-IIIA lung adenocarcinoma patients with EGFR mutation (ICWIP Study): study protocol for a randomized controlled trial. Cancer Manag. Res. 12, 4633\u20134643 (2020).","journal-title":"Cancer Manag. Res."},{"key":"2994_CR22","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S1470-2045(13)70355-3","volume":"14","author":"Y Shi","year":"2013","unstructured":"Shi, Y. et al. Icotinib versus gefitinib in previously treated advanced non-small cell lung cancer (ICOGEN): a randomized, double-blind phase 3 non-inferiority trial. Lancet Oncol. 14, 953\u2013961 (2013).","journal-title":"Lancet Oncol."},{"key":"2994_CR23","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1093\/annonc\/mdx359","volume":"28","author":"YK Shi","year":"2017","unstructured":"Shi, Y. K. et al. First-line icotinib versus cisplatin\/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Ann. Oncol. 28, 2443\u20132450 (2017).","journal-title":"Ann. Oncol."},{"key":"2994_CR24","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1056\/NEJMoa2304594","volume":"389","author":"M Tsuboi","year":"2023","unstructured":"Tsuboi, M. et al. Overall survival with osimertinib in resected EGFR-mutated NSCLC. N. Engl. J. Med. 389, 137\u2013147 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2994_CR25","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1200\/JCO.22.02186","volume":"41","author":"RS Herbst","year":"2023","unstructured":"Herbst, R. S. et al. Adjuvant Osimertinib for resected EGFR-mutated stage IB-IIIA non-small cell lung cancer: updated results from the phase III randomized ADAURA trial. J. Clin. Oncol. 41, 1830\u20131840 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2994_CR26","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S2213-2600(17)30262-X","volume":"5","author":"JJ Yang","year":"2017","unstructured":"Yang, J. J. et al. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small cell lung cancer and multiple brain metastases (BRAIN): a multicenter, phase 3, open-label, parallel, randomized controlled trial. Lancet Respir. Med. 5, 707\u2013716 (2017).","journal-title":"Lancet Respir. Med."},{"key":"2994_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1200\/JCO.18.00131","volume":"37","author":"NA Pennell","year":"2019","unstructured":"Pennell, N. A. et al. SELECT: a phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small cell lung cancer. J. Clin. Oncol. 37, 97\u2013104 (2019).","journal-title":"J. Clin. Oncol."},{"key":"2994_CR28","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1001\/jamaoncol.2024.1779","volume":"10","author":"S Dong","year":"2024","unstructured":"Dong, S. et al. Circulating tumor DNA-guided de-escalation targeted therapy for advanced non-small cell lung cancer: a nonrandomized controlled trial. JAMA Oncol. 10, 932\u2013940 (2024).","journal-title":"JAMA Oncol."},{"key":"2994_CR29","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jtho.2021.10.024","volume":"17","author":"S Lu","year":"2022","unstructured":"Lu, S. et al. Efficacy of Aumolertinib (HS-10296) in patients with advanced EGFR T790M+ NSCLC: updated post-National Medical Products Administration approval results from the APOLLO registrational trial. J. Thorac. Oncol. 17, 411\u2013422 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"2994_CR30","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2213-2600(20)30455-0","volume":"9","author":"Y Shi","year":"2021","unstructured":"Shi, Y. et al. Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a phase 2b, multicenter, single-arm, open-label study. Lancet Respir. Med. 9, 829\u2013839 (2021).","journal-title":"Lancet Respir. Med."},{"key":"2994_CR31","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1016\/j.jtho.2022.06.002","volume":"17","author":"S Lu","year":"2022","unstructured":"Lu, S. et al. Efficacy and safety of Befotertinib (D-0316) in patients with EGFR T790M-mutated NSCLC that had progressed after prior EGFR tyrosine kinase inhibitor therapy: a phase 2, multicenter, single-arm, open-label study. J. Thorac. Oncol. 17, 1192\u20131204 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"2994_CR32","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.jtho.2022.08.015","volume":"17","author":"Y Shi","year":"2022","unstructured":"Shi, Y. et al. Efficacy and safety of Rezivertinib (BPI-7711) in patients with locally advanced or metastatic\/recurrent EGFR T790M-mutated NSCLC: A Phase 2b Study. J. Thorac. Oncol. 17, 1306\u20131317 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"2994_CR33","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.jtho.2022.05.011","volume":"17","author":"Y Shi","year":"2022","unstructured":"Shi, Y. et al. Efficacy and safety of limertinib (ASK120067) in patients with locally advanced or metastatic EGFR Thr790Met-mutated NSCLC: a multicenter, single-arm, phase 2b study. J. Thorac. Oncol. 17, 1205\u20131215 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"2994_CR34","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1016\/S1470-2045(22)00382-5","volume":"23","author":"S Lu","year":"2022","unstructured":"Lu, S. et al. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomized, double-blind, multicenter, phase 3 trial. Lancet Oncol. 23, 1167\u20131179 (2022).","journal-title":"Lancet Oncol."},{"key":"2994_CR35","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jama.2024.10613","volume":"332","author":"W Fang","year":"2024","unstructured":"Fang, W. et al. Ivonescimab plus chemotherapy in non-small cell lung cancer with EGFR variant: a randomized clinical trial. JAMA 332, 561\u2013570 (2024).","journal-title":"JAMA"},{"key":"2994_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa2512071","volume":"394","author":"W Fang","year":"2026","unstructured":"Fang, W. et al. Sacituzumab tirumotecan in EGFR-TKI-resistant, EGFR-mutated advanced NSCLC. N. Engl. J. Med. 394, 13\u201326 (2026).","journal-title":"N. Engl. J. Med."},{"key":"2994_CR37","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(25)01811-2","volume":"407","author":"S Lu","year":"2026","unstructured":"Lu, S. et al. Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small cell lung cancer in China (SACHI): interim analysis of a multicenter, open-label, phase 3 randomized controlled trial. Lancet 407, 375\u2013387 (2026).","journal-title":"Lancet"},{"key":"2994_CR38","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","volume":"4","author":"B Han","year":"2018","unstructured":"Han, B. et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 4, 1569\u20131575 (2018).","journal-title":"JAMA Oncol."},{"key":"2994_CR39","doi-asserted-by":"crossref","unstructured":"Fang, W. et al. Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomized controlled trial. BMJ. 389, e085680 (2025).","DOI":"10.1136\/bmj-2025-085680"},{"key":"2994_CR40","unstructured":"Lu, S. et al. AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non-small cell lung cancer with EGFR exon 19 deletion or L858R mutations. J. Clin. Oncol. 40, 3162\u20133171 (2022)."},{"key":"2994_CR41","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/S2213-2600(22)00168-0","volume":"10","author":"Y Shi","year":"2022","unstructured":"Shi, Y. et al. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer (FURLONG): a multicenter, double-blind, randomized phase 3 study. Lancet Respir. Med. 10, 1019\u20131028 (2022).","journal-title":"Lancet Respir. Med."},{"key":"2994_CR42","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/S2213-2600(23)00183-2","volume":"11","author":"S Lu","year":"2023","unstructured":"Lu, S. et al. Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicenter, open-label, randomized phase 3 study. Lancet Respir. Med. 11, 905\u2013915 (2023).","journal-title":"Lancet Respir. Med."},{"key":"2994_CR43","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/S2213-2600(24)00417-X","volume":"13","author":"Y Shi","year":"2025","unstructured":"Shi, Y. et al. Rezivertinib versus gefitinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (REZOR): a multicenter, double-blind, randomized, phase 3 study. Lancet Respir. Med. 13, 327\u2013337 (2025).","journal-title":"Lancet Respir. Med."},{"key":"2994_CR44","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S2213-2600(25)00121-3","volume":"13","author":"Y Shi","year":"2025","unstructured":"Shi, Y. et al. Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small cell lung cancer with EGFR-sensitising mutation: a randomized, double-blind, double-dummy, phase 3 trial. Lancet Respir. Med. 13, 677\u2013686 (2025).","journal-title":"Lancet Respir. Med."},{"key":"2994_CR45","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.jtho.2024.09.027","volume":"19","author":"C Zhou","year":"2024","unstructured":"Zhou, C. & Xiong, A. OA02.04 A phase III study of rilertinib versus gefitinib as first-line therapy for patients with locally advanced or metastatic EGFR-mutated NSCLC. J. Thorac. Oncol. 19, S11 (2024).","journal-title":"J. Thorac. Oncol."},{"key":"2994_CR46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam, S. S. et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N. Engl. J. Med. 382, 41\u201350 (2020).","journal-title":"N. Engl. J. Med."},{"key":"2994_CR47","doi-asserted-by":"crossref","unstructured":"Shi, Y. et al. 36P First-line limertinib versus gefitinib in EGFR-mutated advanced NSCLC: Updated overall survival results from a randomized, double-blind, phase III trial. ESMO Open 11, 106343 (2026).","DOI":"10.1016\/j.esmoop.2026.106343"},{"key":"2994_CR48","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1097\/CM9.0000000000004016","volume":"139","author":"Z Xie","year":"2026","unstructured":"Xie, Z. et al. Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997-2026). Chin. Med. J. 139, 973\u20131007 (2026).","journal-title":"Chin. Med. J."},{"key":"2994_CR49","doi-asserted-by":"publisher","first-page":"6195","DOI":"10.1158\/1078-0432.CCR-18-1542","volume":"24","author":"X Le","year":"2018","unstructured":"Le, X. et al. Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. Clin. Cancer Res. 24, 6195\u20136203 (2018).","journal-title":"Clin. Cancer Res."},{"key":"2994_CR50","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1158\/1078-0432.CCR-16-0966","volume":"23","author":"M Canale","year":"2017","unstructured":"Canale, M. et al. Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors. Clin. Cancer Res. 23, 2195\u20132202 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2994_CR51","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.62347\/LXOS2662","volume":"14","author":"H Xue","year":"2024","unstructured":"Xue, H. et al. The role of m6A methylation in targeted therapy resistance in lung cancer. Am. J. Cancer Res. 14, 2994\u20133009 (2024).","journal-title":"Am. J. Cancer Res."},{"key":"2994_CR52","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jtho.2018.10.150","volume":"14","author":"Y Kim","year":"2019","unstructured":"Kim, Y. et al. Concurrent genetic alterations predict the progression to target therapy in EGFR-mutated advanced NSCLC. J. Thorac. Oncol. 14, 193\u2013202 (2019).","journal-title":"J. Thorac. Oncol."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02994-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02994-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02994-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T23:03:12Z","timestamp":1787871792000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02994-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2994"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02994-w","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]},"assertion":[{"value":"28 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors have completed the ICMJE uniform disclosure form at\n                      \n                      declare no support from any organization for the submitted work; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years; and no other relationships or activities that could appear to have influenced the submitted work.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"354"}}